22 patents
Utility
Oxymetazoline Compositions
9 Nov 23
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Tina DEVRIES, David JACOBS
Filed: 23 Dec 22
Utility
Controlled release dosage form with enhanced pharmacokinetics
8 Aug 23
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
Filed: 5 Apr 21
Utility
Compositions and methods for treating ocular disorders
18 Jul 23
The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Tina deVries, David Jacobs
Filed: 9 May 22
Utility
Oxymetazoline compositions
3 Jan 23
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Tina Devries, David Jacobs
Filed: 25 Apr 22
Utility
Compositions and Methods for Treating Ocular Disorders
1 Sep 22
The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Tina deVries, David Jacobs
Filed: 9 May 22
Utility
Oxymetazoline Compositions
18 Aug 22
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Tina DEVRIES, David JACOBS
Filed: 25 Apr 22
Utility
Compositions and methods for treating ocular disorders
10 May 22
The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Tina deVries, David Jacobs
Filed: 8 Mar 21
Utility
Oxymetazoline compositions
26 Apr 22
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Tina Devries, David Jacobs
Filed: 30 Aug 21
Utility
Compositions and methods for treating ocular disorders
11 Jan 22
The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Tina deVries, David Jacobs
Filed: 8 Mar 21
Utility
Controlled Release Dosage Form
30 Dec 21
The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
Filed: 8 Jul 21
Utility
Oxymetazoline Compositions
16 Dec 21
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Tina DEVRIES, David JACOBS
Filed: 30 Aug 21
Utility
Controlled Release Dosage Form with Enhanced Pharmacokinetics
16 Sep 21
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
Filed: 5 Apr 21
Utility
Oxymetazoline compositions
31 Aug 21
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Tina deVries, David Jacobs
Filed: 21 Jan 21
Utility
Controlled release dosage form
17 Aug 21
The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
Filed: 24 Feb 20
Utility
Compositions and Methods for Treating Ocular Disorders
15 Jul 21
The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Tina deVries, David Jacobs
Filed: 8 Mar 21
Utility
Oxymetazoline Compositions
13 May 21
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Tina deVries, David Jacobs
Filed: 21 Jan 21
Utility
Controlled release dosage form with enhanced pharmacokinetics
27 Apr 21
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
Filed: 31 Dec 19
Utility
Controlled release dosage form
27 Apr 21
The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
Filed: 10 Apr 19
Utility
Dose-dumping resistant controlled release dosage form
29 Jun 20
The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof.
Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
Filed: 5 Feb 19
Utility
Controlled Release Dosage Form
17 Jun 20
The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
Filed: 23 Feb 20